CLINICAL RESEARCH: CLINICAL TRIAL
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics
The alliance study
Michael J. Koren, MD, FACC*,*,
Donald B. Hunninghake, MD, FACC the ALLIANCE Investigators
* Jacksonville Center for Clinical Research, Jacksonville, Florida, USA
University of Minnesota, Minneapolis, Minnesota, USA
Manuscript received May 8, 2004;
revised manuscript received July 9, 2004,
accepted July 13, 2004.
* Reprint requests and correspondence: Dr. Michael J. Koren, Jacksonville Center for Clinical Research, 4085 University Boulevard South, Suite 1, Jacksonville, Florida 32216
(Email: michaelkoren{at}jaxresearch.com).
OBJECTIVES: This study sought to determine if an aggressive, focused low-density lipoprotein cholesterol (LDL-C)-lowering strategy was superior to usual care for coronary heart disease (CHD) patients enrolled in health maintenance organization or Veterans Administration settings.
BACKGROUND: Statin therapy benefits are well established. No prospective, randomized studies have tested strategies to optimize these benefits in a "real-world" setting.
METHODS: A total of 2,442 CHD patients with hyperlipidemia were randomized to either an aggressive treatment arm using atorvastatin or usual care and followed for 51.5 months on average. Atorvastatin-group patients were titrated to LDL-C goals of <80 mg/dl (2.1 mmol/l) or a maximum atorvastatin dose of 80 mg/day. Usual-care patients received any treatment deemed appropriate by their regular physicians. End point assessments were complete in 958 atorvastatin-group and 941 usual-care patients. Partial assessments occurred in 259 patients in the atorvastatin group and 284 patients in the usual care group who did not complete four years of study participation because of adverse events, withdrawn consent, or follow-up loss. The primary efficacy parameter was time to first cardiovascular event.
RESULTS: A total of 289 (23.7%) patients in the atorvastatin group compared with 333 (27.7%) patients in the usual care group experienced a primary outcome (hazard ratio, 0.83; 95% confidence interval 0.71 to 0.97, p = 0.02). This reduction in morbidity was largely due to fewer non-fatal myocardial infarctions (4.3% vs. 7.7%, p = 0.0002). Levels of LDL-C were reduced more (34.3% vs. 23.3%, p < 0.0001) and National Cholesterol Education Program goals (LDL-C <100 mg/dl) more likely met at end-of-study visits (72.4% vs. 40.0%) in patients receiving atorvastatin compared with those receiving usual care.
CONCLUSIONS: An aggressive, focused statin therapy management strategy outperformed usual care in health maintenance organization and Veterans Administration clinic patients with CHD.
|
Abbreviations and Acronyms
| | ALLIANCE = Aggressive Lipid-Lowering Initiation Abates New Cardiac Events study | | CHD = coronary heart disease | | LDL-C = low-density lipoprotein cholesterol | | MI = myocardial infarction |
|
This article has been cited by other articles:
|
|
|
|
 
T. M. Reynolds, A. Mardani, P. J. Twomey, and A. S. Wierzbicki
Targeted versus global approaches to the management of hypercholesterolaemia
Perspectives in Public Health,
September 1, 2008;
128(5):
248 - 254.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. D. Filippatos and D. P. Mikhailidis
Statins and Heart Failure
Angiology,
August 1, 2008;
59(2_suppl):
58S - 61S.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Shepherd, J. J.P. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D. J. Wilson, A. Zuckerman, N. K. Wenger, and for the Treating to New Targets Investigators
Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study
Clin. J. Am. Soc. Nephrol.,
November 1, 2007;
2(6):
1131 - 1139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Agarwal
Effects of Statins on Renal Function
Mayo Clin. Proc.,
November 1, 2007;
82(11):
1381 - 1390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S. Kostapanos, E.N. Liberopoulos, J.A. Goudevenos, D.P. Mikhailidis, and M.S. Elisaf
Do statins have an antiarrhythmic activity?
Cardiovasc Res,
July 1, 2007;
75(1):
10 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. S Houslay, J. Sarma, and N. G Uren
The effect of intensive lipid lowering on coronary atheroma and clinical outcome
Heart,
February 1, 2007;
93(2):
149 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. W. Neil, D. A. DeMicco, D. Luo, D. J. Betteridge, H. M. Colhoun, P. N. Durrington, S. J. Livingstone, J. H. Fuller, G. A. Hitman, and on behalf of the CARDS Study Investigators
Analysis of Efficacy and Safety in Patients Aged 65-75 Years at Randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Diabetes Care,
November 1, 2006;
29(11):
2378 - 2384.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bonovas, K. Filioussi, N. Tsavaris, and N. M. Sitaras
Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
J. Clin. Oncol.,
October 20, 2006;
24(30):
4808 - 4817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Denke, T. Pearson, P. McBride, R. A Gazzara, W. E Brady, and A. M Tershakovec
Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome
Diabetes and Vascular Disease Research,
September 1, 2006;
3(2):
93 - 102.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Shepherd, P. Barter, R. Carmena, P. Deedwania, J.-C. Fruchart, S. Haffner, J. Hsia, A. Breazna, J. LaRosa, S. Grundy, et al.
Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study.
Diabetes Care,
June 1, 2006;
29(6):
1220 - 1226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Pedersen, O. Faergeman, J. J. P. Kastelein, A. G. Olsson, M. J. Tikkanen, I. Holme, M. L. Larsen, F. S. Bendiksen, C. Lindahl, M. Szarek, et al.
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial
JAMA,
November 16, 2005;
294(19):
2437 - 2445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Angerstein, L. Lemberg, and K. B. Keller
LETTERS TO THE EDITORS
Am. J. Crit. Care.,
November 1, 2005;
14(6):
468 - 469.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Krumholz
The Year in Epidemiology, Health Services, and Outcomes Research
J. Am. Coll. Cardiol.,
October 4, 2005;
46(7):
1362 - 1370.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.T. Ong
The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
QJM,
August 1, 2005;
98(8):
599 - 614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. LaRosa, S. M. Grundy, D. D. Waters, C. Shear, P. Barter, J.-C. Fruchart, A. M. Gotto, H. Greten, J. J.P. Kastelein, J. Shepherd, et al.
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
N. Engl. J. Med.,
April 7, 2005;
352(14):
1425 - 1435.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Daskalopoulou, V. G. Athyros, G. Hamilton, and D. P. Mikhailidis
Lipid-Lowering Therapy in Patients with Peripheral Arterial Disease
Journal of Cardiovascular Pharmacology and Therapeutics,
April 1, 2005;
10(2):
145 - 147.
[PDF]
|
|
|
|
